1. ** Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.
Q1 2022
company sales**
€9,674m
+8.6% (+12.6%)
€1.94
We’re off to a good start in 2022
thanks to a strong commitment
to our strategy. We’re proud of
the progress made in Immunology,
with a broad pipeline of 13 potential
new treatments in development.
Paul Hudson
Chief Executive Officer, Sanofi
Company sales and business EPS*
Sales by global business unit
Progress on social impact strategy
Sales by geography
€2,392m
Europe
€3,484m
US
€3,798m
Rest of
the World
For further information on Q1 2022 results
and definitions of financial indicators, please refer
to the press release issued on April 28, 2022 at:
www.sanofi.com/en/investors
* Earnings per share
Q1 2022
business EPS**
€3,566m
Specialty Care
€3,760m
General Medicines
€1,328m
Consumer Healthcare
€1,020m
Vaccines
First sustainability-linked
bond indexed to
access to medicines
Tied to Sanofi’s commitment
to improve access to essential
medicines in 40 of the world’s
poorest countries via its non-profit
unit Sanofi Global Health
Innovation for
vulnerable communities
Sanofi is working with
leading oncology institutions
to tackle the challenge
of pediatric cancer trials
@Sanofi @Sanofi @Sanofi @SanofiaventisTVen
Q1 2022 results
